EML4-ALK fusions are found in about 3% to13% of NSCLC patients [76], and are largely mutually exclusive with alterations in other RTKs or KRAS based on analysis of almost 1700 tumors [77]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.